Ideaya Biosciences

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study tests a new drug called IDE849, alone or with other drugs, in people with cancers that have a protein called DLL3, including small cell lung cancer. The trial has two phases and aims to see if the drug is safe and shrinks tumors. About 208 participants who have already…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This phase 3 trial tests darovasertib, a daily pill, given before standard local therapy (radiation or surgery) for people with uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and avoid eye removal. About 520 participants will be randomly…